

S/N 10/798,081

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Laurent Lecanu et al.	Examiner:	Joanne Hama
Serial No.:	10/798,081	Group Art Unit:	1632
Filed:	March 11, 2004	Docket:	1941.012US1
Title:	ANIMAL MODEL SIMULATING NEUROLOGIC DISEASE		

INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

LAURENT LECANU ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6905

Date

July 17, 2000

By

Monique M. Perdok Shonka
Monique M. Perdok Shonka
Reg. No. 42,989

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 17 day of July.

John D. Gustaf W. Ruppell
Name

John D. Gustaf W. Ruppell
Signature

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/798,081
Filing Date	March 11, 2004
First Named Inventor	Lecanu, Laurent
Group Art Unit	1632
Examiner Name	Hama, Joanne

Attorney Docket No: 1941.012US1



US PATENT DOCUMENTS				
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-5,192,688	03/09/1993	Switzer III, , et al.	09/25/1991
	US-6,172,277	01/09/2001	Tate, B. A., et al.	10/28/1997

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		"International Search Report and Written Opinion for Application No. PCT/US04/07457, date mailed November 5, 2004", 9 pgs		
		AGGLETON, J P., "The contribution of the amygdala to normal and abnormal emotional states.", <u>Trends Neurosci.</u> 16(8), (1993), 328-333		
		AHN, Y. , et al., "Depletion of Intracellular Zinc Induces Protein Synthesis-Dependent Neuronal Apoptosis in Mouse Cortical Culture", <u>Experimental Neurology</u> , 154, (1998), 47-56		
		ARENDT, T. , et al., "Phosphorylation of Tau, A BETA- Formation, and Apoptosis After in Vivo Inhibition of PP-1 and PP-2A", <u>Neurobiology of Aging</u> , 19 (1), (1998), 3-13		
		BEAL, M B., "Does Impairment of Energy Metabolism Result in Excitotoxic Neuronal Death n Neurodegenerative Illness?", <u>Annals of Neurology</u> , 31(2), (Feb., 1992), 119-130		
		BEHL, C. , et al., "Neuroprotection Against Oxidative Stress By Estrogens: Structure -Activity Relationship", <u>Molecular Pharmacology</u> , 51, (1997), 535-541		
		BRAAK, H , et al., "Involvement of precerebellar nuclei multiple system atrophy", <u>Neuropathology and Applied Neurobiology</u> , 29(1), (2003), 60-76		
		BROWN, RACHEL C., et al., "Oxidative stress-mediated DHEA formation in Alzheimer's disease pathology", <u>Neurobiology of Aging</u> , 24(1), (2003), 57-65		
		BUTTERFIELD, D A., et al., "Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid B-peptide 1-42", <u>Peptides</u> , 23(7), (2002), 1299-1309		
		CALHOUN, MICHEAL E., et al., "Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid", <u>Proc Natl Acad Sci U S A.</u> , 96(24), (Nov. 23, 1999), 14088-14093		

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/798,081
Filing Date	March 11, 2004
First Named Inventor	Lecanu, Laurent
Group Art Unit	1632
Examiner Name	Hama, Joanne

Sheet 2 of 5

Attorney Docket No: 1941.012US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CHMIELOWSKA, J. , et al., "Single vibrissal cortical column in the mouse labeled with 2-deoxyglucose.", <u>Exp. Brain Res.</u> , 63(3), (1986),607-19	
		CHRISTEN, YVES , "Oxidative stress and Alzheimer disease", <u>Am J Clin Nutr.</u> , 71(2), (2000),621S-629S	
		DE LA TORRE, J. C., "Vascular basis of Alzheimer's pathogenesis.", <u>Ann. N.Y. Acad. Sci.</u> , 977, (2002), 196-215	
		DODART, J C., et al., "Does my mouse have Alzheimer disease?", <u>Genes Brain Behav.</u> 1(3), (Aug., 2002),142-55	
		ENNACEUR, A , et al., "A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data.", <u>Behav. Brain Res.</u> , 31(1), (1988), 47-59	
		FILE, S. E., et al., "Validity of head-dipping as a measure of exploration in a modified hole-board.", <u>Psychopharmacologia (Berl)</u> , 44(1), (1975), 53-59	
		FLOYD, ROBERT A., "Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases", <u>Neurobiology of Aging</u> , 23(5), (2002), 795-807	
		GOODMAN, YADONG , et al., "Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons", <u>Journal of Neurochemistry</u> , 66(5), (1996), 1836-1844	
		GREEN, A J., "Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt-Jakob disease", <u>Neuropathology and Applied Neurobiology</u> , 28(6), (2002), 427-440	
		GRIFFITH, OWEN W., "Potent and Specific Inhibition of Glutathione Synthesis by Buthionine Sulfoximine (S-n-Butyl Homocysteine Sulfoximine)", <u>The Journal of Biological Chemistry</u> , 254(16), (Aug. 25, 1979),7558-7560	
		HARDY, JOHN A., et al., "Alzheimer's disease: the amyloid cascade hypothesis.", <u>Science</u> , 256(5054), (Apr. 10, 1992),184-185	
		HOLCOMB, LEIGH , "Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes", <u>Nature Medicine</u> , 4(1), (Jan., 1998),97-100	
		HSIAO, KAREN , et al., "Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice", <u>Science</u> , 274(5284), (Oct. 4, 1996), 99-103	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/798,081
Filing Date	March 11, 2004
First Named Inventor	Lecanu, Laurent
Group Art Unit	1632
Examiner Name	Hama, Joanne

Sheet 3 of 5

Attorney Docket No: 1941.012US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		IRIZARRY, MICHAEL C., et al., "APPsw Transgenic Mice Develop Age-related AB Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1", <u>Journal of Neuropathology and Experimental Neurology</u> , 56(9), (Sept., 1997), 965-973	
		JANUS, CHRISTOPHER, et al., "Transgenic mouse models of Alzheimer's disease", <u>Biochimica et Biophysica Acta</u> , 1502(1), (2000), 63-75	
		JANUS, C, et al., "Transgenic mouse models of Alzheimer's disease.", <u>Physiol Behav.</u> , 73(5), (2001), 873-886	
		KHACHATURIAN, ZAVEN S., "Hypothesis on the regulation of cytosol calcium concentration and the aging brain", <u>Neurobiol Aging.</u> , 8(4), (Jul-Aug, 1987), 345-6	
		KOISTINAHU, MILLA, et al., "Specific spatial learning deficits become severe with age in beta -amyloid precursor protein transgenic mice that harbor diffuse beta -amyloid deposits but do not form plaques", <u>Proc Natl Acad Sci U S A</u> , 98(25), (Dec. 4, 2001), 14675-14680	
		LECANU, LAURENT, et al., "Beta-Amyloid and Oxidative Stress Jointly Induce Neuronal Death, Amyloid Deposits, Gliosis, and Memory Impairment in the Rat Brain", <u>Pharmacology</u> , 76(1), (2006), 19-33	
		LEE, J., et al., "The formation of PHF-1 and SMI-31 positive dystrophic neurites in rat hippocampus following acute injection of okadaic acid", <u>Neuroscience Letters</u> , 282(1-2), (2000), 49-52	
		LEUTNER, SILKE, et al., "Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations", <u>Neuroscience Letters</u> , 292(2), (2000), 87-90	
		LEWIS, JADA, et al., "Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP", <u>Science</u> , 293(5534), (Aug. 24, 2001), 1487-1491	
		LOGGI, G., et al., "Morphine effects on mouse locomotor/exploratory activity: test dependency, test reliability, uni- and multi-variate analyses.", <u>Pharmacol. Biochem. Behav.</u> , 38(4), (1991), 817-822	
		LOVELL, M A., et al., "Copper, iron and zinc in Alzheimer's disease senile plaques", <u>Journal of the Neurological Sciences</u> , 158(1), (1998), 47-52	
		MATSUBARA, E, et al., "Vascular Amyloidosis in Neurodegenerative Conditions", <u>Drug News Perspect.</u> 15(7), (Sept., 2002), 439-444	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/798,081
Filing Date	March 11, 2004
First Named Inventor	Lecanu, Laurent
Group Art Unit	1632
Examiner Name	Hama, Joanne

Sheet 4 of 5

Attorney Docket No: 1941.012US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MIYAKAWA, TAIHEI , "Vascular pathology in Alzheimer's disease", <u>Annals New York Academy of Sciences</u> , 977, (2002), 303-305	
		MORRIS, R. , et al., "Developments of a water-maze procedure for studying spatial learning in the rat.", <u>J Neurosci Methods.</u> , 11(1), (1984), 47	
		MUDHER, AMRITPAL , et al., "Alzheimer's disease-do tauists and baptists finally shake hands?", <u>Trends in Neurosciences</u> , 25(1), (Jan., 2002),22-26	
		MULDER, C , et al., "CSF markers related to pathogenetic mechanisms in Alzheimer's disease", <u>The Journal of Neural Transmission</u> , 109(12), (2002), 1491-1498	
		NAG, S , et al., "Chronic intracerebroventricular exposure to beta-amyloid(1-40) impairs object recognition but does not affect spontaneous locomotor activity or sensorimotor gating in the rat", <u>Exp Brain Res</u> , 136(1), (2001), 93-100	
		NAG, S , et al., "Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of beta-amyloid (1-40).", <u>Brain Research Bullentin</u> , 50(4), (1999), 251-262	
		NAGAI, TAKU , et al., "Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress", <u>The FASEB Journal</u> , 17(1), (Jan., 2003),50-52	
		NITTA, ATSUMI , et al., "beta-Amyloid protein-induced Alzheimer's disease animal model", <u>Neuroscience Letters</u> , 170(1), (1994), 63-66	
		OFFEN, D. , et al., "Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease", <u>Brain Research</u> , 854(1-2), (2000), 257-262	
		OLARIU, A , et al., "Memory deficits and increased emotionality induced by beta-amyloid (25-35) are correlated with the reduced acetylcholine release and altered phorbol dibutyrate binding in the hippocampus", <u>The Journal of Neural Transmission</u> , 108(8-9), (2001),1065-1079	
		PRATICO, DOMENICO , et al., "Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice", <u>The FASEB Journal</u> , 16(9), (July, 2002),1138-1140	
		PRATICO, DOMENICO , et al., "Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis", <u>The Journal of Neuroscience</u> , 21(12), (June 15, 2001),4183-4187	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/798,081
Filing Date	March 11, 2004
First Named Inventor	Lecanu, Laurent
Group Art Unit	1632
Examiner Name	Hama, Joanne

Sheet 5 of 5

Attorney Docket No: 1941.012US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SIGURDSSON, E. M., et al., "Bilateral Injections of Amyloid-Beta 25-35 into the Amygdala of Young Fischer Rats: Behavioral Neurochemical, and Time Dependent Histopathological Effects", <u>Neurobiol. Aging</u> , 18(6), (1997), 591-608	
		SMITH, MARK A., et al., "Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress", <u>Journal of Neurochemistry</u> , 70(5), (1998), 2212-2215	
		SMITH, MARK A., "Oxidative stress in Alzheimer's disease", <u>Biochimica et Biophysica Acta</u> 1502, (2000), 139-144	
		STAUFENBIEL, MATTHIAS, et al., "Neuron loss in APP transgenic mice", <u>Nature</u> , 395(6704), (1998), 755-756	
		STEIN, THOR D., et al., "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein Is Associated with Increased Levels of Transthyretin and the Activation of Cell Survival Pathways", <u>The Journal of Neuroscience</u> , 22(17), (Sept. 1, 2002), 7380-7388	
		SWITZER III, R C., "Application of silver degeneration stains for neurotoxicity testing", <u>Toxicol Pathol.</u> 28(1), (Jan-Feb 2000), 70-83	
		THAL, DIETMAR R., et al., "Fleecy amyloid deposits in the internal layers of the human entorhinal cortex are comprised of N-terminal truncated fragments of Abeta", <u>Journal of Neuropathology and Experimental Neurology</u> , 58(2), (Feb., 1999), 210-216	
		VOLICER, L., et al., "Involvement of free radicals in dementia of the Alzheimer type: a hypothesis", <u>Neurobiol Aging</u> , 11(5), (Sep-Oct, 1990), 567-71	
		WELLER, R O., et al., "Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain", <u>Neurol Res.</u> 25(6), (Sept 2003), 611-6	
		WINKLER, DAVID T., et al., "Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy", <u>The Journal of Neuroscience</u> , 21(5), (Mar. 1, 2001), 1619-1627	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached